Eterna Therapeutics ERNA 深 滬
等待開盤 02-07 09:30:00 美东时间
0.3763
-0.304
-44.66%
華盛通- 最 高0.4183
- 今 開0.40
- 成交量 392.51万股
- 最 低 0.3105
- 昨 收 0.68
- 總市值 295.53万
- 52周最高 5.547
- 市盈率 靜 --
- 換手率 49.98%
- 52周最低 0.3105
- 委 比 97.20%
- 總股本 785.35万
- 歷史最高 190500.00
- 量 比 32.56
- 振 幅 15.85%
- 歷史最低 0.3105
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ernexa Therapeutics Prices Registered Public Offering Of 21M Shares And Warrants At $0.50 Per Share And Accompanying Warrant
Ernexa Therapeutics Inc. (NASDAQ:ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a
02-06 22:27
Ernexa Therapeutics Selected For Exclusive Japan Entry Acceleration Program, Advancing Cell Therapy Pipeline In Oncology and Autoimmune Disease
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies
01-27 21:48
Ernexa Therapeutics Completes Pre‑IND Meeting With FDA, Secures Pathway To IND And First‑In‑Human Ovarian Cancer Trial In H2 2026
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half
01-06 21:18
Ernexa Therapeutics Presents New Preclinical Data On Its Lead Cell Therapy Candidate, ERNA-101, At ASH Annual Meeting
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead
2025-12-08 21:34
Eterna Therapeutics reports Q3 results
Eterna Therapeutics press release (ERNA): Q3 Operating loss decreased $0.3 million, or 12%, from $2.3 million during the three months ended September 30, 2024 to $2.0 million during the three months ...
2025-11-10 22:12
Reported November 7, 2025: Ernexa Therapeutics Q3 EPS $(0.15) Up From $(73.70) YoY
Ernexa Therapeutics (NASDAQ:ERNA) reported quarterly losses of $(0.15) per share. This is a 99.8 percent increase over losses of $(73.70) per share from the same period last year.
2025-11-10 21:51
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
Ernexa Therapeutics (NASDAQ: ERNA) will present at the Cell & Gene Meeting on the Mesa on October 7, 2025, in Phoenix, Arizona, and virtually. The company will highlight its progress in developing iMSC-based therapies for advanced cancer and autoimmune diseases. Ernexa's pipeline includes ERNA-101 for ovarian cancer and ERNA-201 for autoimmune diseases, both utilizing its synthetic, allogeneic iMSC technology. The presentation will showcase Ernex...
2025-10-01 12:30
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
<p>Ernexa Therapeutics (NASDAQ: ERNA), a company developing innovative stem cell therapies for treating advanced cancer and autoimmune diseases, announced that its CEO, Sanjeev Luther, will participate in a panel discussion at the 5th Annual iPSC Drug Development Summit on October 1 in Boston. The company is advancing a best-in-class approach using engineered induced mesenchymal stem cells (iMSC) derived from induced pluripotent stem cells (iPSC)...
2025-09-29 12:30
Ernexa Therapeutics To Present Preclinical Data On Gene-Modified iPS-Derived MSCs Reprogramming Immune Microenvironment In High-Grade Serous Ovarian Cancer At AACR Conference On September 20
Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented at the inaugural AACR Special
2025-09-17 20:36
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Ernexa Therapeutics will present preclinical data on ERNA-101, its lead cell therapy, at the AACR Special Conference on ovarian cancer. ERNA-101, a synthetic MSC-based therapy derived from iPSCs, aims to restore an immune-active "hot" tumor microenvironment in ovarian cancer, potentially advancing toward clinical trials. The presentation, led by Dr. Michael Andreeff from MD Anderson Cancer Center, highlights the therapy's ability to reprogram the...
2025-09-17 12:30
